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ABSTRACT
Anti-cancer therapies based on oncolytic viruses are emerging
as important approaches in cancer treatment. However, the
eﬀectiveness of these therapies depends signiﬁcantly on the
interactions between the oncolytic viruses and the host immune
response.Macrophages are one of themost important cell types in the
anti-viral immune responses, by acting as a ﬁrst line of defence against
infections. Here, we consider a mathematical approach to investigate
the possible outcomes of the interactions between two extreme
phenotypes of macrophages (M1 and M2 cells) and an oncolytic virus
(VSV), in the context of B16F10 melanoma. We show that polarization
towards either an M1 or M2 phenotype can enhance oncolytic virus
therapy through either (i) anti-tumour immune activation, or (ii)
enhanced oncolysis. Moreover, we show that tumour reduction and
elimination does not depend only on the ratio of M1:M2 cells, but also
on the number of tumour-inﬁltrating macrophages.
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1. Introduction
Oncolytic viruses (i.e. viruses that selectively replicate in, and destroy cancer cells) are
emerging as an important approach in cancer treatment, due to their potential of inducing
systemic anti-tumour immunity in addition to selectively killing cancer cells (Kaufman,
Kolhapp,&Zloza, 2016).However, the eﬀectiveness of these viruses – once they are injected
into the patient – depends not only on the pathogenic nature of virally encoded genes, but
also on the interactions between the virus and the host immune response, which might
impact the ability of the virus to replicate (Kaufman et al., 2016).
One of the most versatile types of immune cells, which is also one of the key regulators
of cancer immunotherapy, as well as of immunotherapy against exogenous infections,
is represented by the macrophages. The macrophages can display diﬀerent phenotypes,
in response to the type, concentration and longevity of exposure to stimulating agents
(Cassetta, Cassol, & Poli, 2011). The two extrememacrophages phenotypes are represented
by theM1 andM2 cells; seeMantovani, Sozzani, Locati, Allavena, and Sica (2002) and Sica
et al. (2008) and also Figure 1. (Note that this M1–M2 classiﬁcation follows the Th1–Th2
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Figure 1. Classification of macrophages phenotypes, where cells are considered as part of a continuum,
with the two extreme phenotypes of macrophages polarization being represented by the classically
activated M1 cells and the alternatively activated M2 cells.
Notes: Tumour progression induces a M1→M2 polarization (Mantovani and Sica, 2010). Recent studies (Allavena and
Mantovani, 2012) have suggested a re-polarization of macrophages towards theM1 anti-tumour phenotype, as a treatment
approach to ensure tumour elimination.
CD4+ T cells classiﬁcation, with the M1 cells being stimulated by Th1 cytokines and the
M2 cells being stimulated by Th2 cytokines (Allavena & Mantovani, 2012).) While it is
widely accepted that the classically activated M1 cells have anti-tumour properties and
the alternatively activatedM2 cells have pro-tumour properties, manymacrophages inside
the tumour microenvironment have markers characterizing mixed phenotypes (Allavena
& Mantovani, 2012; Italiani & Boraschi, 2014; Mantovani & Sica, 2010). Therefore, in
spite of the fact that macrophages often constitute one of the most common cell types
in solid tumours (sometimes forming up to 80% of the total tumour mass; see Jakeman,
Hills, Fisher, & Seymour, 2015), their plasticity makes it diﬃcult to fully understand their
pro-tumour/anti-tumour roles, as well as their pro-viral/anti-viral roles.
As recently emphasized in Denton, Chen, Scott, and Cripe (2016), the macrophages’
role on oncolytic virus therapies is a poorly understood aspect. The M2 macrophages can
support these therapies through the suppression of the anti-viral immune response. The
M1 macrophages may impede oncolytic therapies through the promotion of an anti-viral
immune response that leads to viral clearance, but they also enhance the virus-mediated
activation of the anti-tumour immune response (Denton et al., 2016). The complexity of
the interactions between macrophages and oncolytic virotherapies depends also on the
type of the tumour. It is known, for example, that in the case of glioblastoma oncolytic
therapy with Herpex Simplex Virus (HSV), the M1 macrophages hinder this therapy
(Meisen et al., 2015) (via the TNFα pathway), while the M2 macrophages promote this
therapy (Han et al., 2015) (via the activation of the TFGβ pathway). In contrast, in the case
of pancreatic cancer with HSV, the M1 macrophages help this therapy (Liu et al., 2013)
(via the activation of the GM-CSF pathway).
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Figure 2. (a) Growth of B16F10 tumour cells and (a’) the re-polarization of M1 and M2 macrophages,
as described by data re-drawn from Chen et al. (2011). Here, the authors injected mice with 5 × 106
tumour cells. (b) Growth of B16F10 tumour cells in the presence of VSV treatment, as described by data
re-drawn from Fernandez et al. (2002). Here, the authors injected mice with 5 × 105 tumour cells, and
after palpable tumours were formed (of volumes≈100mm3) the mice were treated with 2× 107 PFU of
wild-type VSV.
It is important to emphasize here that also the oncolytic viruses could inﬂuence the
polarization of tumour-associated macrophages (TAMs) via the induction of tumour-
targeted expression of cytokines that can modulate macrophages activation (Jakeman et
al., 2015).
In this study,we use amathematical and computational approach to propose hypotheses
that could explain the complex roles of M1 and M2 macrophages during oncolytic viral
therapies. Mathematical approaches have been widely used in the past to investigate the
interactions between oncolytic viruses, tumour cells and immune cells – mainly cytotoxic
T cells; see Nowak and May (2000), Wodarz (2001), Wodarz and Komarova (2009),
Friedman et al. (2006), Bajzer, Carr, Josic´, Russell, and Dingli (2008), Dingli et al. (2009),
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Figure 3. Caricature description of the interactions between the tumour cells, oncolytic viruses and the
innate immune responses generated by M1 and M2macrophages.
Paiva, Binny, Ferreira, and Martins (2009), Komarova and Wodarz (2010), Wu, Kirn,
and Wein (2004), Eftimie, Dushoﬀ, Bridle, Bramson, and Earn (2011), Hofacre, Wodarz,
Komarova, and Fan (2012), Rommelfanger et al. (2012), Crivelli, Földes, Kim, and Wares
(2012), Macnamara and Eftimie (2015), Kim, Crivelli, Choi, Yun, and Wares (2015), Ma-
linzi, Sibanda, and Mambili-Mamboundou (2015), Eftimie, Macnamara, Dushoﬀ, Bram-
son, and Earn (2016) and the references therein. The majority of these models focus on
the temporal evolution of viral titres and immune cell responses (which can be com-
pared with available experimental data), thus, being described by ordinary diﬀerential
equations. A few mathematical models focus also on the spatial distribution of viruses
inside solid tumours (Hofacre et al., 2012; Malinzi et al., 2015; Malinzi, Eladdadi, &
Sibanda, 2017; Paiva et al., 2009). Other mathematical models have been derived to
investigate the role of M1 and M2 macrophages on tumour dynamics, including B10F16
melanoma (den Breems& Eftimie, 2016; Eftimie &Hamam, 2017; Louzoun, Xue, Lesinski,
& Friedman, 2014).
Here, we focus on the B16F10 melanoma (due to availability of some tumour and
immune data – see Figure 2 and Section 2.1), and investigate the innate immune responses
generated by theM1 andM2 cells during tumour progression. Moreover, we investigate at
a theoretical level the eﬀects ofM1 andM2 cells on the possible outcomes of oncolytic virus
therapies using a Vesicular Stomatitis Virus (VSV). This virus is particularly attractive for
viral-based immunotherapies due to its tumour speciﬁcity, its rapid replication and its
ability to trigger immune responses (Melzer, Lopez-Martinez, & Altomonte, 2017), and
as such there is data on the eﬀects of VSV on tumour dynamics; see Figure 2(b). We
emphasize that while there are experimental studies that focus on the eﬃcacy of VSV
on B16F10 melanoma and the adaptive and innate immune responses, to our knowledge
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Figure 4. (a)–(a”) Comparison between the numerically simulated dynamics of tumour-M1-M2 cells (in
the absence of any VSV treatment) and the experimental data re-drawn from Chen et al. (2011). Initial
conditions are xu = 5 × 106, xm1 = 103, xm2 = 1. (b)–(b’) Comparison between the numerically
simulated dynamics of tumour-M1-M2 cells in the presence of VSV treatment and the experimental data
re-drawn from Fernandez et al. (2002). Initial conditions are xu(0) = 5×105, xm1(0) = 103, xm2(0) = 1,
xv(0) = xi(0) = 0. The injection of 2 × 107 VSV particles on the day (t = 10) when tumour reaches
≈ 100mm3, and again 3 days later (t = 13), is described by the addition of the following function to
the right-hand side of Equation (1c): H(t) = 2 × 107[Heaviside(t − 10.1) × Heaviside(10.2 − t) +
Heaviside(t − 13.1) × Heaviside(13.2 − t)].
Note: Since the intravenous or intratumoural injection of oncolytic viruses can last from a couple of minutes to a couple of
hours (Hotte et al., 2007; Pecora et al., 2002; Kubo et al., 2011), here we model this aspect by assuming that the injection of
the VSV particles occurs during 10% of the total daytime, i.e. for t ∈ [10.1, 10.2] and t ∈ [13.1, 13.2].
there are no experimental studies that diﬀerentiate the eﬀects of M1 and M2 cells on
the anti-tumour roles of VSV. To this end, we use a simple ODE model that describes
the temporal evolution of cells and virus titres. We ﬁrst parametrize the model based on
diﬀerent published literature studies. Then we show that tumour elimination could be the
result of either the oncolytic therapy or immune therapy. Moreover, we use our model to
shed further light on the contradictory results regarding the roles of M1:M2 ratios vs. the
numbers of M1 and M2 macrophages inside tumours, on the long-term patient survival
(Chen et al., 2011;He et al., 2013;Ma et al., 2010;Ohri, Shikotra,Green,Waller,&Bradding,
2009).We show that in the context of anti-tumour immunity, tumour elimination strongly
depends on the total number of tumour-inﬁltratingmacrophages, and not only on the ratio
of M1:M2 cells. On the other hand, tumour control depends on the ratio of M1:M2 cells
(and not on total number of macrophages). Moreover, in the context of oncolytic therapy,
tumour elimination is associated with large numbers of replicating VSV particles, which
leads also to large numbers of tumour-inﬁltrating macrophages.
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2. Model description
To investigate the eﬀect of M1 andM2macrophages on the anti-tumour oncolytic therapy
with VSV, we consider a simple mathematical model that describes the time evolution of
the following variables: the density of uninfected tumour cells (xu), the density of virus-
infected tumour cells (xi), the density of virus particles (xv), the density ofM1macrophages
(xm1) and the density of M2 macrophages (xm2); see also Figure 3. The time-evolution of
these densities is described by the following equations:
dxu
dt
= rxu
(
1 − xu
K
)
− dvxv xuhvu + xu
− duxu xm1hm + xm2 + dmxu
xm2
hm + xm2 , (1a)
dxi
dt
= dvxv xuhvu + xu
− δixi − dixi xm1hm + xm2 , (1b)
dxv
dt
= H(t) + δibxi − ωxv − δvxv xm1hm + xm2 , (1c)
dxm1
dt
= av1(xi + xv) + au1xu + pm1xm1
(
1 − xm1 + xm2
M
)
− xm1
(
r0m1 + rum1
xu
hu + xu
)
+ xm2
(
r0m2 + rvm2
xv
hv + xv
)
− dexm1, (1d)
dxm2
dt
= au2xu + pm2xm2
(
1 − xm1 + xm2
M
)
+ xm1
(
r0m1 + rum1
xu
hu + xu
)
− xm2
(
r0m2 + rvm2
xv
hv + xv
)
− dexm2. (1e)
These equations incorporate the following biological assumptions:
• The uninfected tumour cells proliferate logistically with rate r, up to a carrying
capacity K . Note that we use logistic growth because some experimental studies
showed evidence of a reduced rate of tumour growth at larger sizes (see e.g. the in vivo
and in vitro growth of various human and rodent solid tumours discussed in Laird
(1964), Looney, Ritenour, and Hopkins (1980) and Guiot et al. (2003)). We assume
that the virus particle infect, at a rate dv , only a certain proportion of the tumour. This
can bemodelled using a saturated term for the tumour–virus interactions (with hu the
half saturation constant for tumour cells infected with the oncolytic virus particles).
The uninfected tumour cells can be eliminated by the M1 cells at a rate du (since high
numbers of inﬁltrating M1 macrophages are associated with good patient prognosis
(Mantovani, Schioppa, Porta, Allavena, & Sica, 2006). However, the presence of M2
cells inhibits the anti-tumour immune response generated by these M1 cells (Sica et
al., 2008). Moreover, these M2 cells support tumour growth through the cytokines
they secrete (Allavena & Mantovani, 2012).
• Thevirus-infected tumour cells die at a rate δi, following viral replication and cell burst
– see also Equation (1c). The infected cells can be detected and eliminated (through
phagocytosis) by the M1 macrophages (Hashimoto, Moki, Takizawa, Shiratsuchi,
& Nakanishi, 2007; Italiani & Boraschi, 2014). The anti-viral eﬀect of M1 cells is
inhibited by the presence of M2 cells.
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• Virus injection is described by function H(t) (usually a pulse-like function; see the
beginning of Section 3 below). The number of viral particles increases following the
burst of infected tumour cells. We denote by b the burst size (i.e. the number of viral
particles released by one infected cell). The half-life of these viral particles is 1/ω.
Moreover, the M1 macrophages can promote an anti-viral immune response, which
leads to early clearance of virus particles at a rate δv (Denton et al., 2016). This viral
clearance can be suppressed by the M2 macrophages (Denton et al., 2016).
• The M1 macrophages are activated, at a rate av1, by viral pathogens and infected
tumour cells that trigger the secretion of pro-inﬂammatory cytokines (such as IFN-
γ ) (Labonte,Tosello-Trampont, & Hahn, 2014). These macrophages could also be
activated, at a small rate au1 , by uninfected tumour cells (if they detect these tumour
cells). The macrophages proliferate logistically at a rate pm1, up to their carrying
capacity M (note that tissue-resident macrophages proliferate via a self-renewal
process rather than through an inﬂux of progenitors (Italiani & Boraschi, 2014).
The re-polarization of M1→M2 macrophages occurs (i) at a constant rate r0m1 (due
to cytokines, such as IL-4, IL-10, TGF-β , which can be produced by diﬀerent types
of healthy and immune cells), and (ii) at a tumour-dependent rate rum1xu/(hu + xu)
(due to the anti-inﬂammatory cytokines produced by the tumour cells, e.g. TGB-
β). The re-polarization of M2→M1 macrophages occurs at a constant rate r0m2
(due to cytokines such as IFN-γ or IL-12 produced by diﬀerent types of cells in
the environment). We note here that some viruses (e.g. SARS-CoV (Labonte et al.,
2014), or paramyxoviruses (Tan et al., 2016)) do beneﬁt from triggering a M2→M1
re-polarization. Moreover, oncolytic viruses can be engineered to carry chemokines
and cytokines that can induce amacrophages polarization towards theM1-phenotype
(Guiducci et al., 2005). We assume that this M2→M1 re-polarization occurs at a rate
rvm2. Finally, the macrophages (M1 and M2) have a half-life of 1/de.
• The M2 macrophages are activated at a rate au2 by cytokines such as IL-4, IL-10,
IL-13, TGF-β , which are usually associated with a tumour-promoting environment
(Labonte et al., 2014). These macrophages proliferate logistically at a rate pm2, up to
their carrying capacity M. The M2↔M1 re-polarization has been discussed in the
previous paragraph.
2.1. Parameter approximation
Before investigating the dynamics of system (1), we ﬁrst need to approximate the values
of the parameters. In the following we discuss the approaches taken to identify (i) the
parameter values associated with tumour dynamics alone, (ii) the parameter values for
the tumour–immune interactions and (iii) the parameter values associated with the virus
dynamics. These values are summarized in Table A2 (Appendix 1).
(i) Tumour dynamics alone. We ﬁrst note that B16 melanoma cells have a doubling
time between 17.2 and 24 h (Danciu et al., 2013; Calvet, André, & Mir, 2014). This
corresponds to a proliferation rate of r ∈ ( ln (2)
(24/24) ,
ln (2)
(17.2/24)
) = (.69, .97)/day. For the
simulations we use an average value of r = .924 corresponding to a doubling time
of 18 h. For the tumour carrying capacityK we focus on the data inChen et al. (2011),
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Figure 5. Dynamics of model (1) for the baseline parameter values listed in Table A2, and for the initial
conditions listed in Table A1. Sub-panel (a) shows the tumour–immune–virus dynamics. Sub-panel (b)
shows log (xv(t)) at four specific days: t = 7, t = 14, t = 21 and t = 28. Sub-panel (c) shows the
percentages of M1 and M2 macrophages in the system, at four specific days: t = 7, t = 14, t = 21 and
t = 28.
Notes: The two horizontal upper lines describe the tumour detection threshold of ≈ 107 cells/vol (see Friberg & Mattson,
1997) and tumour carrying capacity K = 3.3 × 109.
where the maximum recorded tumour volume in the absence of any treatment
was 3300mm3. Assuming that a volume of 1000mm3 contains approximately 109
tumour cells (Friberg&Mattson, 1997), we obtain a carrying capacityK = 3.3×109
cells.
(ii) Immune response. It is known that during steady-state conditions, circulatingmono-
cytes have a half-life of 1–3 days (Yang, Zhang, Yu, Yang, & Wang, 2014), with
some class of murine monocytes (Ly6C−) exhibiting a longer steady-state half-life
of 5–7 days (Italiani & Boraschi, 2014). Moreover, this half-life can be increased by
certain drugs. For example, Ly6C− monocytes in tamoxifen-treated mice can show
a half-life of up to 11 days (Yona et al., 2013). Finally, we need to mention that some
macrophage populations can persist even longer, with macrophages residing in
intestinal lamina propria having a half-life of threeweeks, and alveolarmacrophages
persisting for years (Yona et al., 2013). For the simulations we consider an average
cell death rate of de = .2/day (corresponding to a half-life of 3.4 days). In regard to
the macrophages carrying capacity, we take the approach in Eftimie and Hamam
(2017) and assume thatM = 108.
To approximate the rest of parameters associated with the anti-tumour immune
response,we use a least-squares approach to ﬁtmodel (1)with noVSV (xv = xi = 0)
to the mean of the tumour data, as well as to the levels of M1 andM2 cells on days 7
and 14, as given inChen et al. (2011) (see also Figure 2(a) and (a’)).Note that itmakes
sense to assume that following the injection of 5 × 106 tumour cells into C57BL/6
mice there is an innate immune response; moreover a recorded tumour doubling
time of 18 h for B16F10 cells (Calvet et al., 2014; Danciu et al., 2013), cannot explain
the slow tumour growth in Chen et al. (2011) – see also Figure 2(a). In Figure 4(a)–
(a”) we graph: (a) the time evolution of tumour–immune cells, (a’) a comparison
between numerical tumour growth and tumour data from Chen et al. (2011), and
(a”) a comparison between the numerics and the data for the percentages ofM1 and
M2macrophages in the system at two diﬀerent days: t = 7 and t = 14. The tumour
and immune parameter values (du, hmu , hm, dm, au1 , a
u
2 , pm1, pm2, r
0
m1, r
0
m2, r
u
m1) that
generated these results are listed in Table A2. We note that due to the large size of
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the parameter space, it is possible to obtain also other sets of parameter values that
ﬁt the data in Chen et al. (2011). However, it is not the purpose of this particular
study to identify all these parameter values (especially since these values depend on
the initial conditions of the experimental system and of the mathematical model, as
well as the linear/non-linear interaction terms used in model (1)); rather we focus
on one set of parameter values and investigate the dynamics of the model when we
incorporate the VSV therapy.
We note that to be able to explain the M1:M2 ratios on days 7 and 14, as well as the
slightly higher M1 percentages observed in Chen et al. (2011) on day 7, compared
to the M2 percentages on day 14, we need to have au1 < a
u
2 . Moreover, the M1→M2
re-polarization rate as a result of tumour growth (rum1) needs to be much larger
than the baseline re-polarization rates (r0m1 and r
0
m2). All these diﬀerences between
parameters are captured in Table A2.
(iii) Virus dynamics. The burst size of the VSV varies between 50 plaque-forming units
per cell (PFU/cell) to 8000 PFU/cell, with an average of 2500 PFU/cell (Zhu, Yongky,
& Yin, 2009). Here, we run most of the simulations with baseline parameter b =
2500. Moreover, cells infected with VSV particles are lysed by the virus particles
within 30-40 h post infection (Zhu et al., 2009). We assume an average of 35 h, and
thus, consider δi = ln (2.0)/35 h= .47/day. Regarding the intracellular half-life of
VSV particles, it has been shown by DePolo and Holland (1986) that it can vary
between 5.3 and 12.5 h, depending on the viral mutant. Moreover, the extracellular
half-life of retroviral vectors pseudotyped with VSV-G glycoprotein is between 3.5
and 8h (Hwang and Schaﬀer, 2013). In this study we assume a VSV half-life of 8 h,
which corresponds to a viral death rate ω = ln (2.0)/(8/24)/day = 2.0/day. Finally,
to approximate the rest of the parameters associated with the VSV interactions with
tumour and immune cells, we ﬁt the full model (1) to the mean of B16F10 tumour
growth data following VSV infection, as re-drawn from Fernandez et al. (2002);
see also Figure 4(b)–(b’). The parameter values (av1, dv , di = δv , hu) that generated
these results are listed in Table A2. Again, we need to emphasize that the large
parameter space (including the various choices for the length of the VSV injection
time as described by the function H(t)) and the variety of initial conditions for the
model variables, allows for diﬀerent sets of parameter values to ﬁt the tumour data
in Fernandez et al. (2002).
3. Results
Since the majority of experimental studies in the literature focus on tumour–immune
dynamics in the few days/weeks after the administration of the oncolytic virus, we start
our investigation of model (1) by focusing on the transient behaviour of this system, as
we vary diﬀerent model parameters associated with the viral and immune responses. To
this end, we model the experimental case where ≈5 × 106 tumour cells are injected into
the system. Five days later (when the tumour has grown above a detection threshold of
about 107 cells (Friberg &Mattson, 1997)), 107 VSV particles are injected into the tumour.
Since the injection of VSV particles is usually performed within a couple of minutes/hours,
and the virus starts being eliminated from the system within minutes after the injection
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Figure 6. Dynamics of system (1) as we vary the VSV burst size: (a) b = 500, (b) b = 4500. The lower
horizontal thick line describes the tumour detection threshold, which according to Friberg and Mattson
(1997) is of at least 107 cells, while the upper horizontal line describes the carrying capacity K .
(Kubo et al., 2011; Pecora et al., 2002; Tesfay et al., 2013), we decided to represent this
short injection time with the help of function H(t) = Heaviside(5.2 − t) · Heaviside(t −
5.1) (which is non-zero for 10% of a day, and zero for the rest of the time). Finally, we
assume that when the tumour is injected, the circulating M1 macrophages – which are
the primary host response (Mills & Ley, 2014) – discover within minutes some tumour-
associated antigens (Arnold, Gordon, Baker, &Wilson, 2015). These assumptions translate
into the initial conditions for the numerical simulations that are described in Table A1,
Appendix 1 (i.e. approximately 103/vol M1 macrophages and approximately 100/vol M2
macrophages). Note that we have performed simulations also with zero initial levels of
macrophages (not shown here), and the long-term results are qualitatively similar to the
ones shown throughout the rest of this study.
Starting with these initial conditions, to propagate the solution in time we are using
the predictor–corrector Adams–Bashforth–Moulton method, where the initial steps are
calculated with the help of the fourth-order Runge–Kutta method. For the simulations, we
use a time step of 10−3 (corresponding to minutes, and thus, accounting for the possible
steep changes in the systemdynamics that can occurwithinminutes/hours). In Figures 5–8,
the solutions are shown as they evolve across days.
3.1. Short-term dynamics
We start our numerical investigation into the dynamics on model (1) by showing in
Figure 5 the baseline behaviour of thismodel in the presence of VSV therapy (i.e. dynamics
obtained with the initial conditions listed in Table A1 and the parameter values listed
in Table A2; see Appendix 1). In this case the tumour grows to its carrying capacity K ,
despite the presence of some virus particles and tumour-inﬁltrating macrophages (with
M1>M2 at least up to t = 28). For long-term model dynamics see Appendix 2.
In the following we investigate numerically the eﬀects of changing various para-
meters on the transient dynamics of the tumour–immune–virus system. For now, we
assume that rvm2 = 0 (i.e. the oncolytic virus is not engineered to induce a M2→M1
re-polarization).
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Figure 7. (a) The effect of increasing the re-polarization rate rum1 from the baseline value of .15 to
rum1 = .45. Sub-panels (i) show the dynamics of tumour cells, immune cells and virus particles. Sub-
panels (ii) show the logarithm of the level of VSV particles (ln (xv)) in three different days around the
tumour elimination time: t = 157, t = 158 and t = 159. Sub-panels (iii) show the percentages of M1
andM2 cells in the system at the three different days. (b) The effect of increasing the re-polarization rate
rvm2 from the baseline value of 0 to r
v
m2 = .45. (c) The effect of increasing the re-polarization rate rvm2 to
rvm2 = .45, and the tumour-elimination rate du to du = 1.4 (in response to tumour-associated antigens
on VSV). Sub-panels (ii) and (iii) show the percentages of M1 and M2 cells, and total numbers of M1+M2
cells at three different days: t = 10, t = 20, t = 50.
3.1.1. The eﬀect of diﬀerent VSV burst sizes
Since the VSV-infected cells could produce between 50 and 8000 progeny virus particles
(Zhu et al., 2009) (with virus production depending on cell-to-cell diﬀerences), next
we investigate the eﬀect of changing parameter b within the range b ∈ [500, 4500]
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Figure 8. Dynamics of model (1) as we reduce, for longer term, the parameters du, di , δv that control
the M1 (anti-tumour and anti-viral) immune response. (a) Reduction in parameter values on day t = 4,
before the VSV is injected. (b) Time evolution of tumour cells, immune cells and virus particles. (c)
Percentages of M1 and M2 macrophages on day 15 (when the tumour starts to be reduced) and on day
50 (when the tumour is being kept under control). (d) Total number of macrophages on days 15 and 50.
(as we ﬁx all other parameters at their baseline level – see Table A2). In Figure 6(a) we
observe that for very low values of b, the oncolytic virus is eliminated (and the system
approaches a virus-free state, with the tumour cells at their carrying capacity). As we
increase parameter b past the threshold value b ≈ 4300, the system exhibits oscillations
in the dynamics of the tumour, virus and immune responses (see Figure 6(b)). However,
these oscillations occur after the tumour decreases below the detection threshold of ≈107
cells (Friberg & Mattson, 1997), and thus, the tumour cannot be observed clinically.
3.1.2. The eﬀect of increasing rum1 and r
v
m2
The generally accepted idea is that a re-polarization of M2 macrophages towards the M1
phenotype could improve the outcome of the therapy (Colombo & Mantovani, 2005;
Zheng et al., 2017). Moreover, since viral infections that take place early in life are usually
associated with a higher rate of viral replication due toM2macrophage polarization (Sang,
Miller, & Blecha, 2015), it raises the question of whether a (temporary) maintenance of
the M2 phenotype following viral infection to enhance initial oncolytic viral titres could
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improve the overall anti-tumour response. In the following we investigate: (a) the eﬀect
of increasing the M1→M2 re-polarization rate rum1 and (b) the eﬀect of increasing the
M2→M1 re-polarization rate rvm2 (e.g. by genetically engineering the virus). Figure 7(a)
shows that the increase in rum1 from r
u
m1 = .15 (baseline value) to rum1 = .45 (panels
(a)) leads to tumour elimination as a result of increased viral replication inside the large
tumour. This oncolytic anti-tumour response triggers also a sharp increase in the M1:M2
ratio (and the total number of macrophages), which eventually contributes to the ﬁnal
elimination of the tumour. Note that while the tumour is very large, it is still slightly below
its carrying capacity.
We have also investigated the eﬀect of increasing the M2→M1 re-polarization rate as a
result of usingVSVparticles engineered to carry chemokines and cytokines that can induce
a macrophages polarization towards the M1-phenotype (Guiducci et al., 2005). (Previous
studies have shown that VSV engineered to carry cytokines, such as IL-4, lead to enhanced
anti-tumour activity; see Fernandez et al. (2002).) Figure 7(b) shows the eﬀect of increasing
rvm2 from r
v
m2 = 0 (baseline) to rvm2 = .45 (we choose a rate greater than rum1 = .15 to
ensure a strong polarization towards the M1 phenotype). Although this increase in rvm2
leads to a large M1:M2 ratio, the low rate (du) at which the M1 cells eliminate the tumour
cells does not cause a signiﬁcant reduction in tumour size. In Figure 7(c), we then tested
the assumption that the oncolytic virus also carries a tumour-associated antigen (as done
experimentally in Bridle et al. (2009)), and thus, starting with day 5, when the VSV is
introduced, the tumour-elimination rate du increases to the values of di and δv (the viral
elimination rates): du = 1.4. This leads to a decrease in tumour size below the clinical
detection threshold of ≈107 (Friberg &Mattson, 1997). Here, tumour reduction is mainly
the result of the anti-tumour immune response (i.e. a very large M1:M2 ratio – see sub-
panel (ii)), and not so much of the oncolytic viral response).
Remark 1: Since other mathematical modelling studies discussed the importance of
baseline re-polarization rates on tumour growth/decay (den Breems & Eftimie, 2016;
Eftimie & Hamam, 2017), we also investigate this aspect. However, we observed that
neither the increase in r0m1 (from .001 to .1) nor the increase in r
0
m2 (from .01 to .1) had
any signiﬁcant eﬀect on tumour and viral dynamics, which was similar to the baseline
dynamics shown in Figure 5. The only small diﬀerence was observed when we increased
r0m1 to .1, which lead to a ratio M2:M1> 1 during tumour relapse on for t ≥ 21; in contrast
to the case of M2:M1<1 for t = 21, 28 shown in Figure 5(c).
3.1.3. The eﬀect of reducing theM1 immune response
Because the innate immune response is responsible for the persistence or elimination of
the virus (Alvarez-Breckenridge, Yu, Kaur, Caligiuri, & Chiocca, 2012), next we investigate
the eﬀect of reducing (at the same time) the rate at which the M1 cells can eliminate the
uninfected tumour cells (du), infected tumour cells (di) and viruses (δv). To this end, we
investigate both (A) the long-term reduction in the immune response, and (B) the short-
term reduction in the immune response. Since in the Discussion section we will emphasize
the contradictory experimental results related to the role of M1/M2 cells vs. the M1+M2
tumour-inﬁltrating macrophages, next we pay particular attention to both percentages of
M1/M2 cells and the total number (M1+M2) of macrophages.
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(A) Long-term reduction.We assume that the immune response is reduced (via external
chemical treatment; see Hesketh et al., 2015; Wehner et al., 2007; Zheng et al.,
2017) on day t = 4, before the VSV is injected into the system (at t = 5). Figure
8(a) shows the levels of parameters that are reduced. Figure 8(b) shows that a
reduction in the overall immune response leads to tumour decrease below the
detection threshold of 107 cells (Friberg & Mattson, 1997). Therefore, although the
tumour is not completely eliminated, it cannot be detected clinically, being kept
under control by both the virus and the innate immune response. Note here that
a very large ratio of M1:M2 cells (for example, xm1(50) ≈ 99% and xm2(50) ≈
.1%) does not lead to tumour elimination, suggesting that the numbers of tumour-
inﬁltrating macrophages are also very important on the overall outcome.
(B) Short-term reduction. It is known that VSV induces acute lymphopenia charac-
terized by a reduction in the CD8+ T cells for 2–4 days following virus injection.
However, we do not have any knowledge of a similar phenomenon inmacrophages.
In consequence, we investigate at a theoretical level the eﬀect of temporarily re-
ducing the immune response between day t = 5 (when VSV is injected) and days
t = 8 or t = 30 (the latter day assumes that a longer-time immune reduction is
achieved via additional administration of external chemical molecules which can
inhibit macrophages function; see Wehner et al. (2007) and Hesketh et al. (2015)
or induce macrophages apoptosis (Zheng et al., 2017)). We note in Figures 9(ii) the
reduction in tumour size associatedwith both an increase inVSV and a largeM1:M2
ratio. In regard to long-term survival we remark that the M1:M2 ratio is larger than
70:30 (see sub-panels (iii)). This seems to be consistent with experimental data in
Ohri et al. (2009), which showed that long-time patient survival is associated with
more than 70% M1 islet macrophages and less than 30% M2 islet macrophages.
Moreover, we note in panels (iv) that tumour reduction can be associated with both
low and high numbers of macrophages (see total macrophages on day t = 15). In
fact, in panel (a), tumour reduction is associated with a higher M1:M2 ratio, while
in panel (b) tumour elimination is associated with a larger number of macrophages
(M1+M2) combined with a higher M1:M2 ratio. Similarly, tumour growth can be
associated with both low and high numbers of macrophages (see total macrophages
on day t = 50). However, in this case M1:M2≈ 1; see panel (b)(ii) for t > 60.
Overall, the results presented in Figures 5–9 show that model (1) can exhibit a large va-
riety of unintuitive behaviours, which depend on a variety of combinations of parameters.
These unintuitive behaviours are the result of the feedback interactions between the VSV
particles, macrophages and tumour cells. In Section 3.2, we explore a bit more the eﬀect of
these feedback interactions in the context of a local sensitivity analysis.
3.2. Tumour and VSV sensitivity to parameters
Since many model parameters were estimated, in the following we perform a local
sensitivity analysis to investigate the changes in the uninfected tumour size, as we change
the baseline parameters in Table A2. Because we are interested in identifying the
parameters that can slow down tumour relapse, we focus on changes in tumour size
(and VSV level) on day t = 20, when the tumour usually grows towards its carrying
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Figure 9. Dynamics of model (1) as we reduce, for short-term, the parameters du, di , δv that control
the M1 (anti-tumour and anti-viral) immune response. (a) Reduction in parameter values between days
t = 5 and t = 8. (b) Reduction in parameter values between days t = 5 and t = 30. Panels (i) show the
level of reduced parameters. Panels (ii) show the time evolution of tumour cells, immune cells and virus
particles. Panels (iii) show the percentages of M1 and M2 macrophages on day 15 (when the tumour is
being reduced) and on day 50 (when the tumour is being kept under control). Panels (iv) show the total
number of macrophages on days 15 and 50.
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Figure 10. Relative sensitivity of tumour size on day t = 20, to±80% changes in the baseline parameter
values listed in Table A2.
Notes: Note that we did not include the tumour sensitivity to parameter rvm2, since the baseline value of this parameter is 0.
Neither did we include tumour sensitivity to tumour growth rate (r) and carrying capacity (K ) – since it is expected that the
tumour size is very sensitive to changes in these two parameters (Eftimie et al., 2010).
capacity – see Figure 4(b’). Figures 10 and 11 show the relative changes in xu(20) and
xv(20) as calculated by the formula (Hamby, 1994; Olufsen & Ottesen, 2013):
xu,v
xu,v /
∣∣param
param
∣∣ = xoldu,v (20)−xnewu,v (20)xoldu,v (20) /
∣∣paramold−paramnew
paramold
∣∣, where paramnew = paramold
±80%paramold, and xu,v and param are the ﬁnite diﬀerence approximations of the
derivatives of xu,v and of param. Note that we chose to vary the initial parameter values by
±80% since we aim to explore large parameter ﬂuctuations – especially important since
we do not know the biologically realistic ranges for many of the parameter values (e.g. du,
dm, hvu, hm, av1, a
u
1 , a
u
2 ; see Table A2).
In Figure 10, we remark the large impact that parameters dv , du de, di, δv , δi, b, ω, hm
and rum1 have on decreasing tumour size on day 20 (thus, slowing down tumour relapse).
Here, we ignored the tumour-related parameters r and K (since it is known that they will
cause large changes in tumour size; see Eftimie, Bramson, & Earn, 2010), and focused
only on immune and virus-related parameters. While some parameters (e.g. du, b, ω, rum1)
are expected to have a signiﬁcant impact on tumour growth/decay, the eﬀect of other
parameters (e.g. de, hm – associated with immune responses) was somehow unexpected.
Particularly surprising is that a decrease in the natural elimination rate of macrophages
de (i.e. an increase in the half-life of both M1 and M2 cells) could lead to a signiﬁcant
reduction in tumour size (just above the tumour detection level: xnewu (20) ≈ 3.9×107; not
shown here). This suggests that large numbers of macrophages (both M1 and M2) inside
the tumour microenvironment could keep the tumour under control in the context of
oncolytic virotherapies. This is an unexpected result since in the absence of the virus, large
numbers of tumour-associated macrophages have been shown to correlate with decreased
melanoma patient survival (Jensen et al., 2009; Makitie, Summanen, Tarkkanen, & Kivela,
2001).
To get a better understanding of the interactions between the injected VSV particles
and the tumour-immune system during the transient period when the tumour relapses
(i.e. before t = 25 days), we perform also a sensitivity of VSV on day t = 20 to the
changes (by ±80%) in model parameters. Figure 11 shows the relative changes in the
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Figure 11. Relative sensitivity of VSV on day t = 20, to changes by ±80% in the baseline parameter
values listed in Table A2.
Notes: Note that we focused mainly on sensitivity to immune-related and virus-related parameters, and thus, we ignored
parameters r and K . Further, we ignored parameter rvm2, since its baseline value is 0.
sensitivity coeﬃcient for VSV particles (where, as before, we ignored the tumour-related
parameters r and K). The most important result is related to the non-linear eﬀects that
many parameters have on the VSV level: increasing as well as decreasing dv , di, δv , δi,
b, ω leads to a reduction in the VSV level on day t = 20. Moreover, it is unexpected
that parameters such as ω or δi that enter Equations (1c) and (1b) in a linear fashion,
have such a non-linear eﬀect on the overall VSV dynamics. This is likely the eﬀect of
the feedback between VSV, M1/M2 macrophages and tumour cells. In this context, we
also note that the parameter with the largest impact on VSV level is av1, the rate at which
VSV particles and virus-infected tumour cells activate the M1 macrophages (which then
eliminate the VSV particles). Moreover, increasing/decreasing av1 by 80% aﬀects VSV with
diﬀerent intensities: a decrease in av1 leads to a bigger change in VSV level compared to
an increase in av1. Overall, these sensitivity results suggest that individual-level variations
in the parameters associated with the immune responses could have unexpected eﬀects on
the persistence of oncolytic viruses and their anti-tumour roles during transient tumour
dynamics.
4. Discussion
In this paper, we considered a mathematical modelling and computational approach to
investigate the complex interactions between an oncolytic virus (VSV) and the innate
immune response generated by the M1 and M2 macrophages, which can be found in-
side solid tumours. While it is recognized that macrophages play a critical role in the
anti-tumour immune response and the anti-viral immune response, their role on
oncolytic viral therapies is a poorly understood aspect. Moreover, since various
experimental studies emphasized the role of M1:M2 ratio as a tumour prognostic factor
(Chen et al., 2011; He et al., 2013; Herwig, Bergstrom, Wells, Höller, & Grossniklaus,
2013; Zhang et al., 2011), we also paid particular attention to the percentages of M1
and M2 cells in the system, and their interactions with the VSV particles. In addition,
since other studies suggested that it is not the M1/M2 ratio itself but the densities of
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tumour-inﬁltrating macrophages that could predict long-term survival (Edin et al., 2012),
we also calculated the total number of macrophages in the system for some cases where
the tumour was eliminated, kept under control by the immune response, or grew to very
large sizes.
We showed that changes in the tumour-induced re-polarization rate rum1 and the
virus-induced re-polarization rate rvm2 can lead to tumour elimination or reduction
to very low sizes (see Figure 7). In this case, tumour elimination is the result of
oncolytic therapy (see Figure 7(a)), while tumour reduction and control at very low sizes
is the result of very high M1:M2 ratios – but not large numbers of tumour-inﬁltrating
macrophages (see Figure 7(c)). Additional simulations (not shown here) concluded that
changes in the baseline M1↔M2 re-polarization rates r0m1, r0m2 do not aﬀect signiﬁcantly
tumour dynamics, but they might aﬀect the M1:M2 ratios that characterize tumour
relapse (see Remark 1). This was slightly diﬀerent from the simulations in den Breems
and Eftimie (2016) and Eftimie and Hamam (2017), and was likely the result of the
very low baseline values for r0m1, r
0
m2 (which were obtained by ﬁtting model (1) to data
in Chen et al. (2011)).
In regard to the controversy related to the importance of large M1:M2 ratios vs.
large/small numbers of tumour-inﬁltrating macrophages on long-term patient survival
(Edin et al., 2012; He et al., 2013; Ohri et al., 2009), our numerical results showed that in
the context of VSV oncolytic therapy, in some cases the M1:M2 ratio is important (see
Figure 6(c), 7(c), 8 and 9(a)), while in other cases the total number of tumour-inﬁltrating
macrophages (M1+M2) is important (see Figure 9(b)), and the results depend on various
interaction rates and on the level of VSV infection. Therefore, the complexity of the tumour
microenvironment allows for various treatment outcomes, and thus, we might not be able
to use separately either the M1:M2 ratio or the number of M1 and M2 cells inﬁltrating
the tumour as prognostic factors for long-term patient survival. However, combining
both these factors could allow us to make predictions on long-term survival. Moreover,
the importance of both numbers and percentages of M1 and M2 cells could have some
impact on the current approaches used to deal with tumour-inﬁltrating macrophages in
the context of improving cancer therapies (i.e. inhibition of macrophages recruitment into
the tumours, induction of macrophages apoptosis, or re-polarization of M2 macrophages
towards an M1-like phenotype; see Zheng et al., 2017).
Since in Chen et al. (2011) the authors showed only the percentages of M1 and M2
macrophages, we could not test the model against experimental data on total macrophages
levels. (This emphasizes the necessity of having detailed experimental data to be able to
make accurate quantitative and qualitative predictions on treatment outcomes.) However,
we note that for the numerical simulations to reproduce the experimental results in Chen
et al. (2011), higher levels of activemacrophages would requiremuch lower tumour-killing
and tumour-promoting rates (du and dm). Therefore, the values of du and dm listed in Table
A2 could be seen as upper threshold values for these two rates.
In regard to the interactions between the oncolytic virus (VSV) and macrophages, we
note that higher virus levels (≈1011PFU/vol) could lead to an increase in the macrophages
population (bothM1 andM2 cells; see Figure 7(a)), since theM1macrophages are assumed
to respond to foreign pathogens (and M1 cells then re-polarize into M2 cells). Moreover,
long-term investigation of the dynamics of system (1) showed that higher VSV levels could
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lead to (I) tumour elimination (see Figures 7 and B3(c)-in Appendix 2), or (II) tumour
persistence associatedwith larger tumours andmoreM2 cells; see FigureB3(c) inAppendix
2. This dual elimination/persistence result, which is an outcome of the complex feedback
interactions between the components of the system, could explain the contradictory results
on tumour treatments in the literature (both in terms ofM1:M2 ratios and numbers (He et
al., 2013; Ohri et al., 2009), and in terms of the friend/foe roles that macrophages have on
oncolytic viruses in the context of diﬀerent tumours (Denton et al., 2016)). The importance
of the complex feedback interactions between the oncolytic virus and the immune innate
response on overall model dynamics became clear in the sensitivity analysis, where we
observed the non-linear eﬀect that changes in some interaction rates has on the level of
VSV particles on day t = 10 (see Figure 11).
Finally, we acknowledge that the macrophages interact with other immune cells in the
microenvironment (e.g. CD8+ T cells, CD4+ T cells, NK cells), which also have a role in
tumour elimination. The purpose of this study was not to investigate all these possible
immune interactions, but rather to focus on the pro-tumour and anti-tumour eﬀects of
M2 andM1macrophages and their eﬀects on the oncolytic virus therapy. The interactions
between the macrophages and other immune cells (e.g. CD8+ T cells) are the subject of a
future study.
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Appendix 1. Summary of model variables and parameters
Tables A1 and A2 summarize the variables (and their initial values) and the parameters that appear
in system (1).
Table A1. Summary of initial conditions used for the numerical simulations of system (1).
Variable Description Initial conditions
xu Density of uninfected tumour cells (cell numbers per volume) xu(0) = 5 × 106
(Chen et al., 2011)
xi Density of virus-infected tumour cells (cell numbers per volume) xi(0) = 0
xv Density of virus particles (described as particles forming units (PFU) per
volume)
xv(0) = 0
xm1 Density of M1 macrophages (cell numbers per volume) xm1(0) = 103
xm2 Density of M2 macrophages (cell numbers per volume) xm2(0) = 1
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Table A2. Summary of model parameters and their values used throughout this study. The baseline
parameter values used in the simulations are shown in parentheses, under the range values for the same
parameters.
Param. Value Units Description & references
r .924 days−1 Proliferation rate for tumour cells (Danciu et
al., 2013)
K 3.3 × 109 cells/vol Carrying capacity for the tumour cells Chen et
al. (2011)
dv .0036 (cells/vol)× Infection rate of tumour cellswith the oncolytic
(PFU/vol)−1 virus
×(days)−1
du 1.0 days−1 Rate at which M1 macrophages eliminate
uninfected tumour cells
dm .2 days−1 Rate at which M2 macrophages support
tumour growth
hvu 10
5 (cells/vol) Half-saturation constant for the tumour cells
infected with the oncolytic virus
hm 103 (cells/vol) Half-saturation constant for macrophages that
support half the maximum immune response
(leading to tumour elimination or tumour
growth)
δi .47 days−1 Rate at which the oncolytic virus kills an
infected tumour cell (Zhu et al., 2009)
di 1.4 days−1 Rate at which the M1 macrophages eliminate
the infected tumour cells
b 500-8000 (PFU/vol)× Number of virus particles released from an
(2500) (cells)−1(vol) infected cell, capable of forming plaques (Zhu
et al., 2009)
ω 2.0 days−1 Death rate of oncolytic virus particles)
δv 1.4 (cells/vol)× Rate at which the M1macrophages eliminate
(PFU/vol)−1 × the virus particles
(days)−1
av1 2.4 × 10−4 days−1 Activation rate ofM1macrophages in response
to viral antigens
au1 5 × 10−8 days−1 Activation rate ofM1macrophages in response
to viral antigens
au2 1 × 10−7 days−1 Activation rate ofM2macrophages in response
to tumour growth factors (TGF-β) or type-II
cytokines in the tumour microenvironment
pm1 10−3 days−1 Proliferation rate of M1 cells
pm2 10−3 days−1 Proliferation rate of M2 cells
M 108 (cells/vol) Carrying capacity of macrophages
r0m1 .0001–.1 (.001) days
−1 Small baseline M1→M2 re-polarization rate
in response to cytokines in the microenviron-
ment (Wang et al., 2012; Eftimie and Hamam,
2017)
rum1 .015–.45 (.15) days
−1 M1→M2 re-polarization rate in response to
tumour-supporting cytokines & growth factors
r0m2 .0001–.1 (.01) days
−1 Small baseline M2→M1 re-polarization rate
in response to cytokines in the microenviron-
ment (Wang et al., 2012; Eftimie and Hamam,
2017)
rvm2 .0–.45 (0) days
−1 M2→M1 re-polarization rate in response to
engineered viruses
hv 10 (PFU/vol) Half-saturation constant for the viruses to
trigger a M2→M1 re-polarization
hu 108 (cells/vol) Half-saturation constant for the tumour cells
that can trigger an M1→M2 re-polarization
de .2 days−1 Natural death rate ofmacrophages (Yona et al.,
2013)
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Appendix 2. Long-term dynamics: steady-states
We have seen in Section 3.1 that in the long-term, the dynamics of the system (1) could approach
either a ﬁxed steady-state (see e.g. Figures 5 and 6(a)), or can exhibit a periodic behaviour (see
Figure 6(c) and 8). In the following, we focus on identifying the possible steady-states exhibited by
model (1), and their dependence on various model parameters. It can be easily shown that system
(1) exhibits the following steady-states:
(i) Tumour-free, virus-free, macrophages-free state: (x∗u, x∗i , x∗v , x∗m1, x∗m2) = (0, 0, 0, 0, 0).
(ii) Tumour-free, virus-free,macrophages-present state: (x∗u, x∗i , x∗v , x∗m1, x∗m2)= (0, 0, 0, x∗m1, x∗m2),
where x∗m1 and x∗m2 satisfy the following equation (where we made the assumption that the
M1 andM2macrophages have similar proliferation rates, pm1 = pm2 := pm – see Table A2):
r0m1
r0m2
=
1 + x∗m2x∗m1
1 + x∗m1x∗m2
(B1)
We graph in Figure B1(a) the changes in the ratio of x∗m1/x∗m2 as a function of the ratio
r0m1/r
0
m2. As expected, a larger M1:M2 ratio (i.e. M1>M2) corresponds to a lower baseline
r0m1/r
0
m2 ratio.
(iii) Tumour-present, virus-free, macrophages-present state: (x∗u, x∗i , x∗v , x∗m1, x∗m2) = (x∗u, 0, 0,
x∗m1, x∗m2), with the non-zero variables given implicitly as follows:
x∗u = K +
K
r
dmx∗m2 − dux∗m1
hm + x∗m2
, (B2a)
(au2 − au1)x∗u + 2x∗m1rum1
x∗u
hu + x∗u
= x∗m2(2r0m2 + de) − x∗m1(2r0m1 + de). (B2b)
We graph in Figure B1(b) the changes in the steady-state levels of M1 and M2 cells, as we
vary the baseline re-polarization rates r0m1 and r
0
m2. Note that an increase in r
0
m1 leads to
states with larger levels of x∗m2 cells and lower levels of x∗m1 cells (i.e. lower M1:M2 ratios).
In contrast, an increase in r0m2 leads to states with lower levels of x
∗
m2 cells and higher levels
of x∗m1 cells (i.e. higher M1:M2 ratios). Note that it is possible to have also steady-states with
no M1 macrophages (x∗m1 = 0). The small ﬁgure on the right shows that for x∗m1, x∗m2 > 104,
there are new solution branches, characterized by x∗m1 > x∗m2 (in the presence of tumours).
The bottom ﬁgure shows the level of uninfected tumour cells xu as a function of M1 andM2
macrophages. Note that small (or zero) tumours exist for ratios ofM1 : M2 > 1, while large
tumours exist for ratios ofM1 : M2 < 1.
(iv) Tumour-present, virus-present, macrophages-present state: (x∗u, x∗i , x∗v , x∗m1, x∗m2), where the
variables satisfy the following equations:
0 = r
(
1 − x
∗
u
K
)
− dvx
∗
v
hvu + x∗u
− dux
∗
m1
hm + x∗m2
+ dmx
∗
m2
hm + x∗m2
, (B3a)
x∗i =
dvx∗vx∗u
(hvu + x∗u)
(
δi + dix
∗
m1
hm+x∗m2
) , (B3b)
0 = dvx
∗
u
(hvu + x∗u)
(
δi + dix
∗
m1
hm+x∗m2
) −
1
δib
(
ω + δvx
∗
m1
hm + x∗m2
)
, (B3c)
0 = av1(x∗i + x∗v ) + x∗u(au1 − au2) − 2x∗m1
(
r0m1 + rum1
x∗u
hu + x∗u
)
+ 2x∗m2
(
r0m2 + rvm2
x∗v
hv + x∗v
)
− dex∗m1 + dex∗m2. (B3d)
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We can simplify these equations if we solve Equation (B3a) for x∗v and substitute it, together
with Equation (B3b), into Equation (B3c). The solution is now given by the intersection of
the following two surfaces in the (x∗m1, x∗m2, x∗u) space:
S1 : 0 = dvx
∗
u
(hvu + x∗u)
(
δi + dix
∗
m1
hm+x∗m2
) −
1
δib
(
ω + δvx
∗
m1
hm + x∗m2
)
, (B4a)
S2 : 0 = av1
[
r
(
1 − x
∗
u
K
)− dux
∗
m1 − dmx∗m2
hm + x∗m2
][hvu + x∗u
dv
+ x
∗
u
δi + dix
∗
m1
hm+x∗m2
]
+ x∗u(au1 − au2) − de(x∗m1 − x∗m2) − 2x∗m1
(
r0m1 + rum1
x∗u
hu + x∗u
)
+ 2x∗m2
⎧⎨
⎩r
0
m2 +
rvm2
( hvu+x∗u
dv
)[
r
(
1 − x∗uK
)− dux∗m1−dmx∗m2hm+x∗m2
]
hv +
( hvu+x∗u
dv
)[
r
(
1 − x∗uK
)− dux∗m1−dmx∗m2hm+x∗m2
]
⎫⎬
⎭ . (B4b)
We graph in Figure B2(a) the intersection curve between surfaces S1 and S2 as given by
Equation (B4), for the baseline re-polarization rates r0m1 = .001 and r0m2 = .01. First note that
these steady-states exist only for very large tumours (of more than 107 cells). An unexpected
result (which explains also the long-term dynamics in Figures 6 and 8) is that the lower
tumour states are characterized by a lower level of tumour-inﬁltrating macrophages, and if
x∗m1 < 2 × 103 then x∗m1 < x∗m2 (see the projection onto the (x∗m1, x∗m2) plane in the right
ﬁgure of panel (a)). In contrast, if x∗m1 > 2× 103 then the state will have x∗m1 > x∗m2. The low
level of tumours is explained by high VSV values.
In Figure B2(b) we note that an increase in r0m2 leads to a slight increase of the x
∗
u state, while
an increase in r0m1 leads to a slight decrease in x
∗
u- see the small right ﬁgure in panel (b). Since
x∗v is incorporated into these intersection curves, this increase/decrease in x∗u is the result of
changes in x∗v values, as shown below in Figure B3.
Figure B3 shows the relation between x∗u, x∗m1 and x∗m2 for four diﬀerent x∗v values. For low
VSV values (panels (a),(b)), smaller tumours persist and are associated with x∗m1 > x∗m2.
Note here that larger tumours can also persist and are associated with either x∗m1 ≥ x∗m2 or
xm1 ≤ x∗m2. This explains the numerical results in Figs. 6(b),(c), 8, 9. For higher VSV values
(panels (c),(d)), only large tumours can exist (the smaller tumours being eliminated), and in
this case x∗m2 ≥ x∗m1. The elimination of small and medium-sized tumours for VSV ≥ 1010
is consistent with the numerical simulations in Figure 7.
Since we are mainly interested in those cases where tumour is eliminated, in the following we
focus only on the ﬁrst two types of steady-states, (i) and (ii), and investigate their stability – to identify
the biological and mathematical conditions for which system (1) can approach such steady-states.
• It can be easily shown that the tumour-free, virus-free, macrophages-free state (i) is always
unstable (since the ﬁrst eigenvalue of the Jacobian matrix associated with system (1) and
calculated at the state (0, 0, 0, 0, 0) is λ1 = r > 0). Therefore, we do not expect this system to
approach (for a very long time) a state where the tumour and the virus are eliminated and
there is no persistent immune response. However, since this state is a saddle point, solution
trajectories could approach this state along the stable manifold, and move away from the state
along the unstable manifold.
• The stability of the tumour-free, virus-free, macrophages-present state (ii) depends on the
model parameters, as the ﬁve eigenvalues of the Jacobian matrix associated with system (1)
and calculated at the state (0, 0, 0, x∗m1, x∗m2) are
λ1 = −dux
∗
m1 − dmx∗m2 − rx∗m2 − rhm
hm + x∗m2
, (B5)
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(a)
(b)
Figure B1. Virus-free steady-states. (a) Tumour-free, virus-free steady-state (x∗u = x∗i = x∗v = 0): the
ratio of xm1/xm2 as a function of the baseline re-polarization ratio r0m1/r
0
m2; see also Equation (B1); (b)
Tumour-present, virus-free, macrophages-present steady-state (x∗i = x∗v = 0): changes in x∗m1 and x∗m2,
as we vary the baseline re-polarization rates r0m1 and r
0
m2. Bottom figure shows x
∗
u as a function of x
∗
m1
and x∗m2.
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(a)
(b)
Figure B2. (a) Tumour-present, virus-present, macrophages-present steady-state: the curve represents
the intersection of surfaces S1 and S2 given by Equations (B4a) and (B4b), for the baseline macrophages
re-polarization rates r0m1 = .007, r0m2 = .001. (b) The intersection curve for surfaces S1 and S2 as we now
vary the two baseline re-polarization rates: we increase r0m1 to .5 while keeping rm2 = .001 fixed (red
curve), and we increase r0m2 to .5 while keeping rm1 = .001 fixed (green curve).
Note: These changes in r0m1 and r
0
m2 lead to changes in the tumour steady-state x
∗
u .
λ2 = −δvx
∗
m1 + ωx∗m2 + ωhm
hm + x∗m2
≤ 0, (B6)
λ3 = −dix
∗
m1 + δix∗m2 + δihm
hm + x∗m2
≤ 0, (B7)
and λ4,5 satisfying the quadratic equation
λ2 − λ(c11 + c22) + c11c22 − c12c21 = 0, (B8)
with
c11 = pm1
(
1 − 2x
∗
m1 + x∗m2
M
)− r0m1 − de, (B9)
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Figure B3. The relation between uninfected tumour cells (x∗u ), M1 (x∗m1) and M2 (x∗m2) cells, for four
different levels of VSV, as described by Equation (B3a): (a) x∗v = 104PFU/vol; (b) x∗v = 106PFU/vol; (c)
x∗v = 108PFU/vol; (d) x∗v = 1010PFU/vol.
c12 = −pm1x
∗
m1
M
+ r0m2, c21 = −
pm2x∗m2
M
+ r0m1, (B10)
c22 = pm2
(
1 − x
∗
m1 + 2x∗m2
M
)− r0m2 − de. (B11)
This tumour-free state is stable provided that λ1 ≤ 0 and λ4,5 ≤ 0. The inequality λ1 ≤ 0 reduces
to the following inequality for the ratio of M1 and M2 macrophages:
x∗m1
x∗m2
≥ dm + r
du
+ rhm
dux∗m2
. (B12)
This inequality could be satisﬁed if this ratio is greater than one. (Note also in Figure B1(b) bottom
panel, that for x∗m1 > x∗m2 it is possible to have states with no tumours.) The inequality λ4,5 ≤ 0
reduces to c11 + c22 ≤ 0 and c11c22 − c12c21 ≥ 0, or equivalently (since pm1 = pm2)
pm1
(
1 − 3x
∗
m1 + x∗m2
M
)
− 2de ≤ r0m1 + r0m2, (B13)
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and
[
pm1
(
1 − x
∗
m1 + x∗m2
M
)
− de − (r0m1 + r0m2)
][
pm1
(
1 − 2(x
∗
m1 + x∗m2)
M
)
− de
]
≥ 0. (B14)
For the parameter values used in this study (see also Table A2), inequality (B13) holds true since the
term in the left-hand-side is negative (as pm1 	 de < 1). For the same reason, also inequality (B14)
holds true, as each of the two terms in the left-hand-side are negative for the parameter values used
in this study; see also Table A2.
Therefore, for low baseline re-polarization ratios r0m1/r
0
m2 ≤ 1 we can obtain tumour-free states
with high macrophages ratios x∗m1/x∗m2, and these states could be stable thus ensuring permanent
tumour elimination. From a biological point of view, this tumour elimination requires the long-
term persistence of M1 and M2 cells in the system, which might be possible due to recent research
showing the existence of innate immune memory-like behaviours in macrophages (Goodridge et
al., 2016; Yoshida & Ishii, 2016; Yoshida et al., 2015).
